Physician
Mattison Pathology, L.L.P.
Mattison Pathology, L.L.P. was paid $9.71M by Medicaid between Jan 2018 and Oct 2024, across 100 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 14% of everything it billed.
33Billing provider infoMATTISON PATHOLOGY, L.L.P.
DALLAS, TX 75205
DALLAS, TX 75205
33aNPI1063619922assigned 07/02/2007
33bProvider typeCytopathology Physician
28Total paid$9.71M
24GClaims512,330
24DCodes billed100
24AFirst – last monthJan 2018 – Oct 2024
Compared with peers
Next to other Cytopathology Physician providers in Texas
Rank by total paid#1 of 14
Median peer was paid$43K
This provider vs. median227×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,000 | $991K | |
| 2019 | 53,871 | $1.39M | |
| 2020 | 78,194 | $2.38M | |
| 2021 | 131,837 | $2.21M | |
| 2022 | 94,695 | $1.21M | |
| 2023 | 88,966 | $1.35M | |
| 2024incomplete | 10,767 | $181K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 14% | 69,829 | 28,890 | $1.40M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 13% | 65,208 | 61,215 | $1.23M |
| 87481 | 11% | 52,685 | 27,469 | $1.11M | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 11% | 64,857 | 60,922 | $1.09M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 9.9% | 56,393 | 52,917 | $962K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 7.4% | 3,925 | 3,331 | $719K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 5.7% | 43,880 | 41,723 | $551K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 5.3% | 31,969 | 30,329 | $516K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 4.0% | 2,776 | 2,094 | $387K |
| 87511 | 3.3% | 29,856 | 27,618 | $320K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.7% | 6,396 | 4,896 | $259K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 5,482 | 4,486 | $254K |
88 more codes
| 81443 | 2.3% | 345 | $223K | |
| 87653 | 1.7% | 8,518 | $163K | |
| 88141 | 1.1% | 8,684 | $108K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,814 | $54K |
| 87625 | <1% | 3,115 | $45K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,920 | $41K |
| 88142 | <1% | 4,044 | $37K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,139 | $36K |
| 87529 | <1% | 945 | $32K | |
| 87563 | <1% | 1,769 | $29K | |
| 88112 | <1% | 3,064 | $25K | |
| 88342 | <1% | 270 | $10K | |
| 88377 | <1% | 67 | $10K | |
| 87640 | <1% | 318 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 774 | $7K |
| 81329 | <1% | 2,502 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 864 | $4K |
| 87660 | <1% | 211 | $4K | |
| 81243 | <1% | 2,792 | $4K | |
| 87510 | <1% | 211 | $3K | |
| 87480 | <1% | 215 | $3K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 821 | $3K |
| 81257 | <1% | 1,235 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,437 | $3K |
| 80081 | <1% | 315 | $3K | |
| 86780 | <1% | 732 | $3K | |
| 81514 | <1% | 90 | $3K | |
| 88307 | <1% | 14 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 221 | $2K |
| 88341 | <1% | 57 | $2K | |
| 81250 | <1% | 1,198 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,199 | $2K |
| 83020 | <1% | 381 | $2K | |
| 86803 | <1% | 401 | $2K | |
| 81255 | <1% | 1,197 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,084 | $1K |
| 81251 | <1% | 1,193 | $1K | |
| 86696 | <1% | 208 | $1K | |
| 84439 | <1% | 340 | $1K | |
| 87340 | <1% | 233 | $1K | |
| 80053 | Comprehensive metabolic panel | <1% | 422 | $1K |
| 80055 | <1% | 94 | $1K | |
| 82951 | <1% | 349 | $957.87 | |
| 86762 | <1% | 177 | $837.04 | |
| 85041 | <1% | 847 | $695.31 | |
| 88120 | <1% | 14 | $662.06 | |
| 82728 | <1% | 99 | $629.39 | |
| 80074 | <1% | 40 | $612.53 | |
| 80061 | Lipid panel | <1% | 112 | $592.49 |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | <1% | 26 | $569.83 |
| 88313 | <1% | 14 | $548.97 | |
| 84153 | <1% | 146 | $502.47 | |
| 80050 | General health panel | <1% | 14 | $455.46 |
| 84702 | <1% | 72 | $428.59 | |
| 86703 | <1% | 316 | $384.99 | |
| 83525 | <1% | 83 | $346.40 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 184 | $283.15 |
| 88304 | <1% | 12 | $237.16 | |
| 86592 | <1% | 474 | $214.85 | |
| 87088 | <1% | 74 | $196.25 | |
| 83001 | <1% | 40 | $195.39 | |
| 81001 | <1% | 161 | $175.98 | |
| 82950 | <1% | 231 | $168.58 | |
| 87186 | <1% | 57 | $152.99 | |
| 87070 | <1% | 32 | $132.03 | |
| 87341 | <1% | 45 | $125.96 | |
| 81401 | <1% | 298 | $115.31 | |
| 83002 | <1% | 14 | $113.73 | |
| 87077 | <1% | 50 | $108.23 | |
| 88302 | <1% | 13 | $103.48 | |
| 84146 | <1% | 14 | $102.72 | |
| 87081 | <1% | 152 | $69.09 | |
| 87015 | <1% | 18 | $69.07 | |
| 86140 | <1% | 30 | $67.95 | |
| 86704 | <1% | 13 | $65.04 | |
| 85027 | <1% | 27 | $31.46 | |
| 82947 | <1% | 18 | $9.90 | |
| 81330 | 0% | 507 | $0.00 | |
| 81209 | 0% | 503 | $0.00 | |
| 81242 | 0% | 503 | $0.00 | |
| 81400 | 0% | 509 | $0.00 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 54 | $0.00 |
| 81200 | 0% | 503 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 3,170 | $0.00 |
| 81422 | 0% | 82 | $0.00 | |
| 81205 | 0% | 515 | $0.00 | |
| 81260 | 0% | 504 | $0.00 | |
| 81290 | 0% | 505 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLGAMOT, GREGORY (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Northwest Pathology PLLC | Bellingham, WA | $17.79M |
| Mattison Pathology, L.L.P. | Lubbock, TX | $558K |
| Northwest Pathology PLLC | Bellingham, WA | $77K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.